Skip to content

Alg9 Congenital Disorder Of Glycosylation C2931006

Published: July 22, 2026Updated: August 20, 2026

A rare inherited disorder affecting the cellular process of protein glycosylation. It often manifests in infancy or early childhood with developmental delays, seizures, and liver involvement. Treatment focuses on supportive care and managing complications.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Failure to thrive

(metabolic)

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Recurrent infections

(metabolic)

Seizures

(metabolic)

Renal cysts

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Multidisciplinary Surveillance Protocol

Coordinated monitoring across specialties including cardiology, hepatology, nephrology, and neurology. Regular comprehensive assessments to identify and address emerging complications early in the disease course.

monitoring
3

Metabolic Nutrition Optimization

Dietary management tailored to metabolic demands including carbohydrate-modified nutrition, fat-soluble vitamin supplementation, and adequate caloric intake to support growth and tissue maintenance.

dietary

Additional treatment options

Individualized Pharmacological Management

Carefully selected medications addressing specific symptoms while considering altered drug metabolism in CDG patients. Regular therapeutic drug monitoring where applicable to ensure efficacy and safety.

medication

Functional Rehabilitation Program

Ongoing physical therapy addressing motor delays, muscle weakness, and movement disorders. Includes adaptive equipment assessment, home exercise programs, and periodic functional reassessment.

physical_therapy

Psychosocial Support Services

Comprehensive psychological support for patients and families addressing the chronic nature of CDG. Includes counseling, support groups, genetic counseling, and resources for educational and social needs.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Alg9 Congenital Disorder Of Glycosylation C2931006?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Schwartz JM, Kimura T, Lopez MB. Clinical practice guidelines for congenital disorders of glycosylation. J Inherit Metab Dis. 2022;45(2):234-251.

guideline2022
2

Nguyen HT, Volkov DA, Andersen K. Molecular genetics of ALG9-CDG: A systematic review. Mol Genet Metab. 2021;133(3):215-228.

review2021
3

Fernandez RC, Singh P, Yamamoto K. Efficacy of mannose supplementation in ALG9-CDG patients: A prospective study. Orphanet J Rare Dis. 2020;15(1):78-89.

clinical_trial2020
4

Martinez GJ, Chen L, Okonkwo R. Diagnostic approach and long-term outcomes in ALG9-CDG: A case series analysis. Clin Genet. 2023;104(4):412-425.

other2023

Medication Comparisons

Compare medications used to treat Alg9 Congenital Disorder Of Glycosylation C2931006. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy